Neurogene (BST:UU8) - Stock Price, News & Analysis

UU8 Stock Overview

A biotechnology company, develops genetic medicines for rare neurological diseases. More details

UU8 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 83.32% per year

Risk Analysis

Shares are highly illiquid

Makes less than USD$1m in revenue ($925K)

Earnings are forecast to decline by an average of 29.9% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Neurogene Inc. Competitors

2invest

XTRA:2INV

€62.7m

Heidelberg Pharma

XTRA:HPHA

€105.8m

Formycon

XTRA:FYB

€857.2m

Biotest

XTRA:BIO3

€1.3b

Price History & Performance

Summary of all time highs, changes and price drops for Neurogene
Historical stock prices
Current Share Price	US$26.00
52 Week High	US$39.33
52 Week Low	US$14.70
Beta	0
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-30.41%

Recent updates

Shareholder Returns

	UU8	DE Biotechs	DE Market
7D	64.6%	-1.1%	1.1%
1Y	n/a	-18.8%	7.2%

Return vs Industry: Insufficient data to determine how UU8 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how UU8 performed against the German Market.

Price Volatility

Is UU8's price volatile compared to industry and market?
UU8 volatility
UU8 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: UU8's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine UU8's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	91	Rachel McMinn	www.neurogene.com

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC.

Neurogene Inc. Fundamentals Summary

How do Neurogene's earnings and revenue compare to its market cap?
UU8 fundamental statistics
Market cap	€376.77m
Earnings (TTM)	-€3.10m
Revenue (TTM)	€874.68k

430.8x

P/S Ratio

-121.6x

P/E Ratio

Is UU8 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UU8 income statement (TTM)
Revenue	US$925.00k
Cost of Revenue	US$57.65m
Gross Profit	-US$56.73m
Other Expenses	-US$53.45m
Earnings	-US$3.28m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.22
Gross Margin	-6,132.86%
Net Profit Margin	-354.16%
Debt/Equity Ratio	0%

How did UU8 perform over the long term?

See historical performance and comparison

Neurogene BST:UU8 Stock Report